Arcutis: Affiliate files Form 144 to sell 30,000 shares

Arcutis Biotherapeutics Inc. notice: proposed sales of Common Stock by Howard Welgus reported on a Form 144.

Rhea-AI Filing Summary

Arcutis Biotherapeutics Inc. notice: proposed sales of Common Stock by Howard Welgus reported on a Form 144. The excerpt lists three dispositions of 10,000 shares each on 02/02/2026, 03/02/2026, and 04/01/2026 with proceeds shown as $250,482.69, $256,517.50, and $238,800 respectively.

Security details include Common Stock trading on NASDAQ and a reported shares outstanding figure of 124,033,382 shares as of 05/01/2026.

Insights

Securities Counsel

Routine Form 144 notice of proposed sales by an affiliate; filings record transaction dates and gross proceeds.

The excerpt lists three reported dispositions by Howard Welgus totaling 30,000 shares across three dates: 02/02/2026, 03/02/2026, and 04/01/2026

These entries are notice filings under the resale rules; actual execution, settlement, or broker methods are not detailed in the provided excerpt. Subsequent public reports or broker records would show final sale mechanics and net proceeds.

Key Figures

Shares reported sold (per entry): 10,000 shares Proceeds (02/02/2026): $250,482.69 Proceeds (03/02/2026): $256,517.50 +2 more

5 metrics

Shares reported sold (per entry) 10,000 shares each reported disposition on 02/02/2026, 03/02/2026, 04/01/2026

Proceeds (02/02/2026) $250,482.69 gross amount shown for 10,000 shares on 02/02/2026

Proceeds (03/02/2026) $256,517.50 gross amount shown for 10,000 shares on 03/02/2026

Proceeds (04/01/2026) $238,800 gross amount shown for 10,000 shares on 04/01/2026

Shares outstanding 124,033,382 shares as of 05/01/2026

Key Terms

Form 144, Stock option exercise, Common (NASDAQ)

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Stock option exercise financial

"Stock option exercise | Arcutis Biotherapeutics Inc"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Common (NASDAQ) market

"Common | Merrill 8890 Lyra Dr ... | NASDAQ"

FAQ

What does the ARQT Form 144 filing show?

It shows proposed sales of Common Stock by Howard Welgus reported on Form 144. The excerpt lists three dispositions of 10,000 shares each on 02/02/2026, 03/02/2026, and 04/01/2026 with gross proceeds displayed.

How many ARQT shares were reported sold by Howard Welgus in the excerpt?

The excerpt lists three reported dispositions totaling 30,000 shares. Each line shows a separate 10,000 share entry on specific dates with corresponding gross proceeds in dollars.

What proceeds are listed for the ARQT transactions?

The excerpt lists gross proceeds of $250,482.69, $256,517.50, and $238,800 for the three 10,000-share entries. These appear as the dollar amounts accompanying each sale date.

Does the filing state how the ARQT shares will be sold?

The excerpt includes a note of a prior "Stock option exercise" and labels the recent lines as securities sold; it does not specify sale methods (brokerage, block trade) or settlement details in the provided text.

How many ARQT shares were outstanding per the excerpt?

The excerpt lists 124,033,382 shares outstanding as of 05/01/2026. That figure appears in the securities information block and is shown with the date provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:04 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801050
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ARCUTIS BIOTHERAPEUTICS, INC.
SEC File Number	001-39186
Address of Issuer	3027 Townsgate Road Suite 300 Westlake Village CALIFORNIA 91364
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Howard Welgus
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr 5th Floor Columbus OH 43240	7144	164219.71	124033382	05/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2018	Stock option exercise	Arcutis Biotherapeutics Inc			7144	06/04/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	03/02/2026	10000	256517.5
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	02/02/2026	10000	250482.69
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	04/01/2026	10000	238800

144: Remarks and Signature

Remarks
Date of Notice	05/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/11/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Howard Welgus
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)